Rallybio

RLYBNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$89.907 M

$16.93 -1.51%

Close of 21 Sept 2026

Revenue

$858.0K

#3491 by revenue

Earnings

-$8.98M

Loss-making

Shares outstanding

5,310,499

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#312Citius OncologyCTOR$97.2M
#313Anixa BiosciencesANIX$93.9M
#314RallybioRLYB$89.9M
#315Acrivon TherapeuticsACRV$86.1M
#316Telomir PharmaceuticalsTELO$85.3M

What if Rallybio were worth as much as…

Open the what-if tool →

Gold $30.3T

$5,700,793

Per share 336,727× higher

Bitcoin $1.72T

$323,849.74

Per share 19,129× higher

Nvidia $5.48T

$1,031,891

Per share 60,950× higher

Or at a round number

$200.0M $500.0M $1.00B $2.00B

Where these numbers come from

Share counts and financials for Rallybio are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.